The high prevalence of cigarette smoking in patients with respiratory disease puts them at risk of developing clinically important drug interactions. Cigarette smoking reduces the therapeutic response to certain drugs such as theophyllines through the induction of hepatic cytochrome P450 isoenzymes. Smokers with asthma and patients with COPD have reduced sensitivity to corticosteroids, possibly due to non-eosinophilic airway inflammation, altered glucocorticoid receptor activity or reduced histone deacetylase activity. Although all smokers should be encouraged to stop smoking, there is limited information on the influence of smoking cessation on the therapeutic and anti-inflammatory effects of a number of the drugs used in the treatment of respiratory disease.
Introduction
The World Health Organization estimates that there are 1.25 billion smokers worldwide, with approximately two-thirds living in developing countries. Prevalence rates of smoking are higher in countries with lower incomes and in poor socioeconomic groups within individual countries. The estimated overall smoking prevalence rate for Europe is around 28.6% (40% among males and 18.2% among females) [The European Tobacco Control Report, 2007] . Prevalence figures for the US show rates of 23.9% in men and 18.1% in women [CDC, 2006] . In most western countries, the prevalence of smoking has reduced since the 1970s, but the rate of decline has leveled out over the last 5 years [Walker et al. 2002; CDC, 2006 CDC, , 2007 .
Active cigarette smoking and exposure to environmental cigarette smoke (ETS) are strongly associated with the development of respiratory diseases such as chronic obstructive pulmonary disease (COPD) [Mannino and Buist, 2007] and lung cancer [Doll et al. 2004] . Cigarette smoking rates are higher in patients with these diseases than are found within the general population. Cigarette smoking is a risk factor for the development of idiopathic interstitial pneumonia including idiopathic pulmonary fibrosis [IPF, 2000] . The sub-types of IPF strongly associated with cigarette smoking are respiratory bronchiolitis-associated interstitial lung disease Correspondence to:
(RBILD), desquamative interstitial pneumonia (DIP), and Langerhans' cell histiocytosis [Wells et al. 2007; Caminati and Harari, 2006; IPF, 2000; Vassallo et al. 2000 ], whereas hypersensitivity pneumonitis, cryptogenic organizing pneumonia [Cordier, 2006; ATS/ERS, 2002] and radiation pneumonitis occur less commonly in cigarette smokers. Active smoking and exposure to ETS are implicated as risk factors for the development of asthma [Thomson, 2007a] . The prevalence of cigarette smoking in patients with asthma is similar to that found in the general population [Tyc and Throckmorton-Belzer, 2006; Yun et al. 2006 ; Thomson et al. 2004; Silverman et al. 2003 ]. The high prevalence of cigarette smoking in patients with respiratory disease puts them at risk of developing clinically important drug interactions. This review will focus on the mechanisms and effects of cigarette smoking on the therapeutic response to commonly prescribed drugs for patients with respiratory disease.
Mechanisms for altered efficacy of drugs in cigarette smokers
Cigarette smoking alters the therapeutic response to drugs used to treat respiratory diseases through several mechanisms including induction of hepatic isoenzymes, by pharmocodynamic interactions as well as through reduced sensitivity to corticosteroids [Livingston et al. 2005 ].
The mechanism causing altered efficacy of some drugs in smokers, such as heparin, is not known [Kroon, 2007] .
Hepatic isoenzyme induction
Various constituents of tobacco smoke including nicotine, acetone, pyridine, benzene, carbon monoxide and heavy metals have been implicated as enzyme inducers altering the pharmacokinetic and pharmacodynamic properties of many drugs [Zevin and Benowitz, 1999] . Polycyclic aromatic hydrocarbons in tobacco smoke are alleged to produce the most significant alterations in drug availability by their induction of hepatic cytochrome P450 (CYP) isoforms [Zevin and Benowitz, 1999] . Drugs for which induced metabolism by cigarette smoking may have clinical consequence include theophyllines, through the induction of CYP1A2 isoform. The efficacy of drugs that are used to treat non-pulmonary disorders in smokers with respiratory disease are also altered through CYP enzyme induction such as anti-depressants (fluvoxamine), anti-psychotics (olanzepine, clozapine) and anti-arrhythmics (flecainide) [Kroon, 2007; Livingston et al. 2005; Zevin and Benowitz, 1999] . The reduction in CYP1A2 activity following smoking cessation may have significant implications on drug clearance. Clinically this is important in drugs with a narrow therapeutic range, such as theophylline.
Pharmocodynamic interactions
Drugs such as benzodiazepines and beta blockers down-regulate the sympathetic nervous system, and possibly in part because nicotine in cigarette smoke activates this system, larger doses of these drugs are required to achieve the same therapeutic effect in smokers [Zevin and Benowitz, 1999] .
Corticosteroid insensitivity
The therapeutic response to corticosteroids is impaired in smokers with asthma compared with non-smokers with asthma and in patients with COPD. The evidence for this phenomenon is examined later. The cause of reduced corticosteroid sensitivity in smokers is probably multi-factorial and may involve one or more of the following mechanisms [Thomson et al. 2004] .
a. Inflammation phenotype Variations in inflammatory cell phenotype and alterations in cytokine responses in smokers compared with non-smokers may be in part explain reduced sensitivity to corticosteroids. Eosinophilic inflammation in the airways predicts an enhanced response to corticosteroids in both asthma [Little et al. 2000 ] and COPD [Brightling et al. 2005] . Sputum eosinophil numbers are reduced in some smokers with asthma, particularly in those with a heavy smoking history, compared to non-smokers [Chalmers et al. 2001 ]. An observational study noted that an elevated sputum eosinophil count predicted a good therapeutic response to corticosteroids in patients with asthma, including some smokers, suggesting that the presence or absence of airway eosinophils may be an important factor in determining corticosteroid responsiveness in smokers with asthma [Bacci et al. 2006 ]. Sputum neutrophil counts are raised in heavy smokers with asthma [Chalmers et al. 2001 [Chalmers et al. , 2002 Boulet et al. 2006 ], although not in those with mild disease [Lazarus et al. 2007 ] and in COPD [Chanez et al. 2004] . The presence of increased neutrophil numbers may contribute to reduced sensitivity to corticosteroids, since neutrophilic inflammation is less sensitive to corticosteroids. Cigarette smoking increases production of pro-inflammatory cytokines IL-4, IL-8 and TNF-α, induces oxidative stress and activates pro-inflammatory transcription factors such as nuclear factor-κB (NF-κB), all mechanisms implicated in causing corticosteroid insensitivity in asthma and COPD [Kharitonov, 2003; Hawrylowicz et al. 2002; Franchimont et al. 1999; Kam et al. 1993 ].
b. Glucocorticoid receptor subtypes A reduction in ligand-activated glucocorticoid receptor α subtype numbers or over expression of the non-functional glucocorticoid receptor β subtype might impair response to corticosteroids [Lewis-Tuffin and Cidlowski, 2006; Leung and Bloom, 2003] . In support of this mechanism contributing to corticosteroid insensitivity in smokers, the ratio of the glucocorticoid receptor α to β isoforms is reduced in peripheral blood mononuclear cells from current smokers compared with never smokers including patients with asthma [Livingston et al. 2004] . Corticosteroid-induced nuclear translocation of glucocorticoid receptors could potentially be impaired in smokers and contribute to corticosteroid insensitivity. c. Histone deacetylase activity Corticosteroids activate histone deacetylase activity (HDAC) to reduce transcription of inflammatory genes [Barnes, 2004] . Smokers with COPD have decreased HDAC2 activity in alveolar macrophages, Review and this may lead to increased inflammatory gene expression and reduced sensitivity to corticosteroids in subjects with COPD [Cosio et al. 2004a [Cosio et al. , 2004b Ito et al. 2001 ] with a similar mechanism possibly accounting for reduced corticosteroid sensitivity in smokers with asthma [Barnes, 2004] . In addition, the p38 mitogen-activated protein kinase signaling pathway is activated in COPD [Renda et al. 2008] and possibly also in smokers and in severe asthma [Irusen et al. 2002; Mochida-Nishimura et al. 2001] , which might impair the anti-inflammatory effects of corticosteroids.
d. Pharmacokinetics
Tobacco smoke might reduce the local availability of inhaled corticosteroid at key target cells within the airways due to increased airway mucosal permeability [Ilowite et al. 1988; Kennedy et al. 1984] , mucus production [Cerveri et al. 2003; Lange et al. 1998] or impaired deposition of drug within the lungs [Invernizzi et al. 2004] . These mechanisms do not explain the decreased response to oral corticosteroids [Chaudhuri et al. 2003] or the reduced vasoconstrictor response to topical corticosteroids in smokers with asthma [Livingston et al. 2007 ].
Adherence with therapy
It is possible that smokers with respiratory disease may be less adherent to therapy than non-smokers, as compliance with clinical preventive practices is worse in smokers [Galan et al. 2006 ]. However in several clinical studies demonstrating corticosteroid insensitivity in smokers with asthma, the adherence with corticosteroid therapy, as assessed by inhaler weight measurement [Chalmers et al. 2002] or tablet counts [Chaudhuri et al. 2003] , was similar in smokers and non-smokers with asthma.
Corticosteroids in smokers
Asthma National and International guidelines recommend the use of corticosteroids in the treatment of chronic persistent asthma and acute severe asthma [BTS, 2003; GINA-Report, 2006 ]. However, there is increasing evidence that smokers with chronic asthma have an attenuated response to treatment with corticosteroids. The first evidence for this phenomenon was provided by a randomized controlled trial of inhaled corticosteroids in patients with mild to moderately severe obstructive airways disease, either asthma, COPD or mixed disease, in which current smokers had reduced efficacy from treatment with 800 mcg daily of inhaled beclometasone compared with non smokers [Kerstjen et al. 1995] . A post hoc analysis of a clinical trial of the long-term effects of low or high dose inhaled budesonide on indices of asthma control and inflammation showed improvements in lung function, use of rescue medication and biomarkers of eosinophilic inflammation in nonsmokers with asthma, but not in the smoking group [Pedersen et al. 1996] .
Since these earlier studies, Chalmers et al. [2002] conducted the first prospective randomized controlled trial demonstrating corticosteroid insensitivity in smokers with asthma. This was a cross-over study comparing the effect of three weeks treatment with inhaled fluticasone propionate, 1000 mcg daily, or placebo to 17 smokers and 21 non-smokers with corticosteroid-naïve asthma. Outcome measures of increase in mean morning PEF, increase in FEV 1 and airway hyperresponsiveness to methacholine and decrease in proportion of sputum eosinophils after fluticasone compared with placebo were significantly greater in smokers compared with non-smokers. A further study addressed the question whether a longer duration of treatment with inhaled corticosteroids could overcome the insensitivity and compared low dose with high dose inhaled corticosteroids [Tomlinson et al. 2005] . Ninety-five patients, including smoking and non-smoking individuals with mild asthma, were randomized to treatment with inhaled beclometasone 400 mcg or 2000 mcg daily for 12 weeks in smokers and non-smokers. In the group receiving 400 mcg daily, the improvement in mean morning PEF was greater in non-smokers compared to smokers and the number of asthma exacerbations (2 versus 6) decreased in non-smokers compared to smokers ( Figure 1 ). There was no significant difference between the outcome measures in the groups of smokers and non-smokers assigned to the 2000 mcg beclometasone, with both groups demonstrating an improvement in morning PEF. The results of this exploratory trial suggest that it may be possible to overcome corticosteroid insensitivity using high doses of inhaled corticosteroids [Tomlinson et al. 2005] , but this strategy could put patients at risk of long term adverse effects [Barnes et al. 1998 ]. The Asthma Clinical Research Network in the USA conducted a multi-center randomized cross-over trial recruiting forty-four non-smoking asthmatics and thirty-nine smokers with asthma to treatment with inhaled CFC-free beclometasone ('QVAR TM ') in a dose of 400 mcg daily (equivalent to 800 mcg of CFC-beclometasone) or placebo for 12 weeks [Lazarus et al. 2007 ].
The therapeutic response to inhaled beclometasone was attenuated in the smokers, but not in the non-smokers. A post hoc analysis performed on the results of the Gaining Optimal Asthma Control (GOAL) trial, which compared the efficacy of inhaled fluticasone alone or combined with inhaled salmeterol over one year, found increased exacerbation rates in smokers receiving inhaled fluticasone compared to never-smokers (0.35 vs 0.17 per patient per year). This result provides evidence of insensitivity to long term treatment with inhaled corticosteroids [Pedersen et al. 2007] (Figure 2 ). However, the reduced therapeutic response to corticosteroids may not apply to all smokers with asthma [Jang et al. 2005] . A study of 86 patients with moderate to severe asthma, 19 of whom were smokers, found that smoking status did not influence the therapeutic response to corticosteroids [Jang et al. 2005 ]. Administration of inhaled corticosteroid for a long duration might have beneficial effects on the rate of decline in lung function [Dijkstra et al. 2006; Lange et al. 2006 ], but this effect appears to be lost in those with a heavy smoking history [Dijkstra et al. 2006 ].
Reduced sensitivity to corticosteroids in smokers with chronic asthma may extend to short-term treatment with oral prednisolone 40 mg daily [Chaudhuri et al. 2003 ]. An exploratory randomized controlled crossover trial of 14 smokers, 10 ex-smokers and 26 never-smokers with asthma investigated the response to oral corticosteroids or placebo for two weeks. Improvements in FEV 1 , morning PEF and symptom control scores occurred in the never-smoking group but not in the current smokers group (Figure 3 ). An interesting finding was the partial response in the ex-smokers group suggesting that corticosteroid insensitivity is at least partially reversible by smoking cessation. Smokers with asthma have an impaired cutaneous vasoconstrictor response to topical corticosteroids [Livingston et al. 2007] compared to never-smokers with asthma suggesting that the insensitivity to corticosteroids in smokers with asthma affects tissue sites other than the airways. A post hoc analysis of a clinical trial performed in children with mild persistent to severe asthma that compared the administration of drug treatment either at school or away from school suggested a reduced therapeutic effect of inhaled corticosteroids in children exposed to ETS at home [Halterman et al. 2004] .
COPD Several systematic reviews have concluded that inhaled corticosteroids administered for at least . Comparison for exacerbation rates was made by adjusting for baseline, stratum, sex, age, smoking status, and smoking by treatment interaction. Reproduced from [Pedersen et al. 2007] with permission from the publishers. 6 months for stable COPD demonstrate a beneficial effect in reducing rates of exacerbations Alsaeedi et al. 2002] , slowing the decline in health status ] and reducing neutrophilic airway inflammation [Gan et al. 2005] . In COPD, alveolar macrophages and indices of airway inflammation are resistant to short-term treatment with corticosteroids [Culpitt et al. 2003; Keatings et al. 1997 ]. Longterm use of inhaled corticosteroids does not reduce the rate of decline in FEV 1 [Soriano et al. 2007; Yang et al. 2007] or mortality ], but does increase the probability of developing pneumonia [Calverley et al. 2007a] . Only a few studies have examined the influence of cigarette smoking on the efficacy of inhaled corticosteroids in COPD. A Cochrane review concluded that smoking status did not predict the beneficial response to inhaled corticosteroids ]. In support of this conclusion, the deterioration in exacerbation rates after inhaled fluticasone withdrawal is similar in current smokers compared to ex-smokers with COPD [Wouters et al. 2005 ]. However, a pooled analysis of 7 long-term controlled trials of inhaled corticosteroids lasting 12 months or longer in patients with mild to moderate COPD (n = 3, 911) found that continued smoking attenuated the increase in FEV 1 related to inhaled corticosteroid therapy during the first 6 months of treatment [Soriano et al. 2007 ]. During the first 6 months of treatment male ex-smokers had a 45 ml increase in FEV 1 compared to 37 ml increase in male current smokers (p < 0.05) and female ex-smokers had a 65 ml increase in FEV 1 compared to a 20 ml increase in female current smokers (P < 0.01) [Soriano et al. 2007 ]. Analysis of the same group of patients reported a survival benefit from inhaled corticosteroids in former smokers (adjusted hazard ratio 0.60; 95% (A) (B) p = 0.605 p = 0.865 p = 0.108 p = 0.004 A reduction in the score implies an improvement in asthma control. Reproduced from [Chaudhuri et al. 2003 ] with permission from the publishers.
CI 0.39 to 0.93), but not in current smokers (adjusted hazard ratio 0.87; 95% CI 0.59 to 1.22) . Interestingly in patients with COPD current smoking is the factor most strongly associated with a reduced change in FEV 1 after oral prednisolone [Burge et al. 2003 ].
Idiopathic interstitial pneumonia
Corticosteroids are the most commonly used therapy for most forms of idiopathic interstitial pneumonia including idiopathic pulmonary fibrosis [Paramothayan and Jones, 2002; IPF, 2000] .
Corticosteroids are also used to treat smokingrelated forms of idiopathic interstitial pneumonia such as bronchiolitis-associated interstitial lung disease (RBILD), desquamative interstitial pneumonia (DIP), and Langerhans' cell histiocytosis, particularly when there is no improvement following smoking cessation or when functional impairment is severe [Wells et al. 2007; Vassallo et al. 2000 ]. Severity adjusted survival from IPF is higher in non-smokers than in former and current smokers [Antoniou et al. 2008] .
The response to corticosteroids in the different types of idiopathic interstitial pneumonia is very variable and it is not known whether it is specifically influenced by smoking status [Rudd et al. 2007; IPF, 2000] .
Combination therapy in smokers

Asthma
Combination therapy with an inhaled corticosteroid and a long acting beta 2 receptor agonist has a central role in the management of chronic asthma [GINA Report, 2006a] . A post hoc analysis performed on outcome measures in smokers with asthma enrolled in the GOAL trial, which compared the efficacy of inhaled fluticasone alone or combined with inhaled salmeterol over one year, found reduced exacerbation rates with combination therapy compared to inhaled fluticasone alone (0.20 vs 0.35 per patient per year) ( Figure 2 ) [Pedersen et al. 2007] . For patients treated with inhaled salmeterol/fluticasone combination the exacerbation rate was higher in current smokers compared to patients who had never smoked (0.20 vs 0.13 per patient per year) ( Figure 2) .
COPD
Combination therapy with inhaled fluticasone and salmeterol or inhaled budesonide and formoterol reduces the rate of exacerbations and improves health status and lung function of patients with COPD [Wedzicha et al. 2007; Szafranski et al. 2003; Calverley et al. 2003a Calverley et al. , 2003b Calverley et al. , 2007a . All-cause mortality is not significantly reduced by combination therapy with inhaled fluticasone and salmeterol [Calverley et al. 2007a ]. The combination of inhaled salmeterol and fluticasone given for 3 months reduces a range of inflammatory cells, including CD8+T cells, CD4+T cells and macrophages (CD68+) in bronchial biopsy specimens [Bourbeau et al. 2007; Barnes et al. 2006 ] and neutrophil numbers in induced sputum [Barnes et al. 2006 ]. Smoking status has been reported not to influence the response to combination-therapy in COPD [Calverley et al. 2003a; Szafranski et al. 2003 ], although some relevant studies do not comment on the potential interaction between smoking status and treatment response [Calverley et al. 2003b [Calverley et al. , 2007a . Racial factors may influence the therapeutic response to combination-therapy, since Chinese patients with COPD show improvements in lung function with the combination of inhaled CD8+ p = 0.09 p = 0.015 CD45+ p = 0.057 p = 0.030 TNFα mRNA+ p = 0.016 p = 0.093 CD68+ p = 0.58 p = 0.267 CD4+ p = 0.07 p = 0.093 Mast cells p = 0.83 p = 0.007
Change favours SALM/FP
Change favours placebo
IFNγ mRNA+ p = 0.29 p = 0.02 ; Former smokers: ; * Median difference for salmeterol/fluticasone propionate (SALM/FP) minus placebo. p-values for the median treatment difference are provided for current smokers and for former smokers. (Lower limit of 95% confidence limit for CD45+ cells in former smokers is -867 cells/mm 2 ). Reproduced from Barnes et al. [2006] with permission from the publishers. salmeterol and inhaled fluticasone in former or current smokers, but not in never smokers [Zheng et al. 2007 ]. Interestingly the antiinflammatory effects of inhaled salmeterol and fluticasone on bronchial biopsies in COPD reported that the response to combination treatment were generally similar in smokers and former smokers, albeit the magnitude of reduction was generally greater in the former smokers ( Figure 4) [Barnes et al. 2006 ].
Leukotriene receptor antagonists in smokers
Current asthma guidelines suggests a role for leukotriene receptor antagonist in adults and children older than 5 years as alternative, but less effective first line prophylactic agents to inhaled corticosteroids [GINA Report, 2006a] . Anti-leukotrienes are also used as alternative add-on drugs for adults and children with persistent symptoms despite low dose inhaled corticosteroid therapy, but in adults these agents are less effective than long-acting beta 2 agonists [Ducharme et al. 2006 ]. The finding from a small proof of concept clinical that the leukotriene receptor antagonist montelukast increases morning PEF values in smokers with mild asthma, but not in non-smokers with mild asthma, suggests that there may be a differential greater effect of leukotriene receptor antagonists in smokers [Lazarus et al. 2007 ]. Further larger studies are required to determine the influence of smoking status on the efficacy of leukotriene receptor antagonists, including data from smokers with moderate and severe disease [Thomson, 2007b] . A larger prospective study of leukotriene receptor antagonists in smokers is reported to be underway, which may help clarify the role of anti-leukotrienes in smokers with asthma [Montelukast Asthmatic Smoker Study, 2006b ].
Theophylline in smokers
Theophylline clearance is increased by 58-100% in smokers compared to non-smokers [Bukowskyj et al. 1984; Jenne et al. 1975 ] through the induction of the metabolizing enzymes CYP1A2 [Zevin and Benowitz, 1999] . The effects are especially seen as age increases. Marijuana smokers who also smoke cigarettes have an increased clearance of theophylline that appears to be additive [Jusko et al. 1978] .
A study of theophylline toxicity in 2766 medical in-patients revealed that adverse reactions were experienced by 13% of non-smokers, 11% of those smoking up to 20 cigarettes per day and by 7% of those who smoked more heavily [Pfeifer and Greenblatt, 1978] . In contrast, abstinence from smoking for a week lead to a 38% decrease in clearance of theophylline [Lee et al. 1987] . Doses of CYP substrates with a narrow therapeutic range should be decreased on cessation of smoking, with Faber and colleagues suggesting a stepwise reduction of 10% a day until the fourth day of smoking abstinence, accompanied by therapeutic drug monitoring [Faber and Fuhr, 2004] . As smoking cessation is often achieved with the help of nicotine replacement, Lee et al. [1987] studied if nicotine gum affected theophylline clearance in smokers and found no effect, suggesting that it is probably other components of smoke such as polyaromatic hydrocarbons rather than nicotine accounting for the rapid clearance of theophylline in smokers.
Exposure to ETS increases the metabolism of theophylline compared to non-smokers [Matsunga et al. 1989 ]. Children with asthma exposed to ETS demonstrated a 51% increase in total body clearance of theophylline compared with asthmatic children not exposed to ETS, implying that children with significant smoke exposure would require higher doses of theophylline to achieve therapeutic levels to control their asthma [Mayo, 2001] .
Selective phosphodiesterase (PDE) 4 inhibitors in smokers
Cilomilast is a systemically available, secondgeneration, selective PDE 4 inhibitor, retaining the therapeutic activity of the first generation phosphodiesterase-4 inhibitors, but believed to have less emetic effects. Smoking has no clinically relevant effects on pharmacokinetics of cilomilast [Schachter, 2006; Murdoch et al. 2004] . A post hoc analysis of a placebo controlled study of cilomilast in current and ex-smokers with COPD found that the improvement in FEV 1 with cilomilast in current smokers was similar to that seen in patients treated with placebo, whereas there was a significant improvement in FEV 1 in ex-smokers [Rennard et al. 2006 ]. In severe, stable COPD, PDE 4 inhibition with roflumilast for 1 year produced a modest improvement in lung function without changing the exacerbation rate or health status. Smoking status did not influence the effect of roflumilast on lung function, exacerbation rate, or quality of life in the population as a whole [Calverley et al. 2007b] . In another study of 24 weeks duration, there were no differences in the therapeutic response to roflumilast between current smokers and ex-smokers [Rabe et al. 2005] . Taken together, the current evidence suggests that the efficacy of selective PDE 4 inhibitors is normally unaffected by smoking status.
Beta 2 Receptor agonists in smokers
There is no published literature on potential pharmacokinetic effects of smoking affecting the clinical response to salbutamol, terbutaline or formoterol. Salbutamol is metabolized by conjugation with sulphate and in a small study of lobectomy samples of the human lung it was found that the rate of sulphation was higher in non-smokers compared to smokers but similar in smokers and ex-smokers [Pacifici et al. 1996 ].
Antimuscarinics in smokers
There is no published literature on potential pharmacokinetic effects of smoking on inhaled ipratropium and inhaled tiotropium. Rennard et al. [1996] compared results of inhaled ipratropium and short acting beta 2 agonists from five clinical trials including 1245 evaluable subjects with COPD and found that there was a clear interaction between smoking status and treatment group. Current smokers improved similarly when treated with ipratropium and short acting beta 2 agonists, but ex-smokers improved only with ipratropium. Smoking status does not influence the ability of tiotropium to reduce COPD exacerbations [Niewoehner et al. 2005] or to improve lung function [Moita et al. 2008 ].
Antibiotics in smokers
There is no evidence to suggest that the pharmacokinetics of antibiotics are altered by smoking. In a small study, the uptake of antibiotics by alveolar macrophages from 15 smokers was compared to the results from a previous study in non-smokers. The antibiotics tested were clinidamycin, erythromycin, chloramphenicol, lincomycin, tetracycline, gentamicin, cefamandole, penicillin G, rifampicin, isoniazid and ethambutol. All the antibiotics entered the alveolar macrophages of smokers as well as non-smokers, but lipid soluble antibiotics such as rifampicin, erythromycin and clindamycin reached higher levels in the macrophages of smokers [Lee Hand et al. 1985] . Macrolides such as azithromycin, but not clindamycin, can improve the phagocytosis of apoptotic bronchial epithelial cells by bronchoalveolar lavage derived alveolar macrophages and neutrophils from normal and current and ex-smoker with COPD subjects, suggesting that smoking status does not adversely affect the prophagocytic activity of azithromycin [Hodge et al. 2006 ].
Review
Other drugs in smokers Heparin metabolism is elevated in smokers, which may necessitate a slight increase in dosage [Cipolle et al. 1981 ]. Warfarin clearance is increased, but this is not associated with a change in prothrombin time [Zevin and Benowitz, 1999] . The effect of smoking status on efficacy of anticoagulants may have important clinical implications given that smokers also have increased prothrombotic tendencies compared to non-smokers. In one study never-smokers were found to have an improved outcome over smokers when treated with chemotherapy for non-small cell lung cancer [Tsao, 2006] .
Management
The interaction of medication and smoking is important to consider when planning treatment. Although all smokers with respiratory disease should be encouraged to stop smoking, there is limited information on the influence of smoking cessation on the efficacy and anti-inflammatory effects of a number of the drugs used in the treatment of respiratory disease. Former smokers with asthma have a better response to oral corticosteroids than current smokers, suggesting that quitting smoking may lead to an improvement in the response to corticosteroids [Chaudhuri et al. 2003 ]. In support of this observation, smoking cessation leads to an increase in the cutaneous vasoconstrictor response to topical corticosteroids at 6 weeks suggesting an increase in the peripheral response to corticosteroids [Chaudhuri et al. 2006 ]. In patients with COPD, inhaled corticosteroid treatment reduces the rate of decline in lung function and mortality rate in ex-smokers to a greater degree compared to current smoker [Soriano et al. 2007; Sin et al. 2005] .
The dose and/or choice of drug may need to be altered when treating smokers compared to nonsmokers with respiratory disease. Evidence from an exploratory clinical trial suggests that high doses of inhaled corticosteroids may overcome the reduced sensitivity to corticosteroids in smokers with asthma [Tomlinson et al. 2005] , although this regimen could put patients at risk of adverse effects from corticosteroids. Combination inhaled corticosteroid and long acting beta 2 agonist reduces exacerbation rates in asthma and COPD compared to inhaled corticosteroids alone, and as this therapeutic effect occurs in smokers, it may be a better option than an increased dose of an inhaled corticosteroid. A recent study suggests beneficial effects of leukotriene receptor antagonists in smokers with mild asthma [Lazarus et al. 2007 ], but results from larger studies are awaited. The bronchodilator effects of ipratropium, salbutamol and tiotropium are not influenced by smoking status. As theophylline clearance is increased in smokers, the dose should be increased in current smokers and reduced after smoking cessation, with monitoring of therapeutic drug levels. Children with significant ETS exposure could require higher doses to achieve therapeutic levels. Heparin metabolism in increased and may require a slight increase in dose in current smokers. No dose alterations need to be made for antibiotics therapy in smokers.
Conclusions
Cigarette smoking can influence the response to medication used in respiratory disease, particularly in patients with asthma or COPD. The most important effects result from increased clearance of theophylline and reduced sensitivity to corticosteroids in smokers with asthma and patients with COPD. The efficacy of drugs that are used to treat non-pulmonary disorders in smokers with respiratory disease are also altered mainly through enzyme induction. The interaction of medication and smoking is important to consider when planning treatment.
